Natera, Inc. (NTRA)
USD 155.2
(-7.73%)
USD 155.2
(-7.73%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 492.74 Million USD | 35.38% |
| 2022 | 363.96 Million USD | 18.53% |
| 2021 | 307.06 Million USD | 63.87% |
| 2020 | 187.38 Million USD | 47.71% |
| 2019 | 126.85 Million USD | 38.49% |
| 2018 | 91.59 Million USD | 28.39% |
| 2017 | 71.34 Million USD | -12.46% |
| 2016 | 81.5 Million USD | 5.15% |
| 2015 | 77.51 Million USD | -4.18% |
| 2014 | 80.89 Million USD | 352.02% |
| 2013 | 17.89 Million USD | 477.66% |
| 2012 | 3.09 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 208.6 Million USD | 30.49% |
| 2024 Q2 | 243.17 Million USD | 16.57% |
| 2023 Q2 | 118.25 Million USD | 26.3% |
| 2023 Q1 | 93.63 Million USD | 4.08% |
| 2023 FY | 492.74 Million USD | 35.38% |
| 2023 Q4 | 159.85 Million USD | 32.12% |
| 2023 Q3 | 120.99 Million USD | 2.32% |
| 2022 Q2 | 88.96 Million USD | -2.15% |
| 2022 Q3 | 94.12 Million USD | 5.8% |
| 2022 Q4 | 89.96 Million USD | -4.42% |
| 2022 FY | 363.96 Million USD | 18.53% |
| 2022 Q1 | 90.91 Million USD | 15.22% |
| 2021 Q2 | 65.91 Million USD | -22.91% |
| 2021 Q4 | 78.9 Million USD | 2.82% |
| 2021 FY | 307.06 Million USD | 63.87% |
| 2021 Q3 | 76.74 Million USD | 16.43% |
| 2021 Q1 | 85.5 Million USD | 62.88% |
| 2020 Q3 | 46.32 Million USD | 17.17% |
| 2020 Q4 | 52.49 Million USD | 13.33% |
| 2020 FY | 187.38 Million USD | 47.71% |
| 2020 Q1 | 49.03 Million USD | 26.45% |
| 2020 Q2 | 39.53 Million USD | -19.38% |
| 2019 Q3 | 34.02 Million USD | 11.46% |
| 2019 FY | 126.85 Million USD | 38.49% |
| 2019 Q4 | 38.77 Million USD | 13.96% |
| 2019 Q1 | 23.52 Million USD | -2.71% |
| 2019 Q2 | 30.53 Million USD | 29.8% |
| 2018 Q1 | 21.74 Million USD | 27.63% |
| 2018 Q3 | 23.6 Million USD | 6.92% |
| 2018 Q4 | 24.17 Million USD | 2.44% |
| 2018 FY | 91.59 Million USD | 28.39% |
| 2018 Q2 | 22.07 Million USD | 1.5% |
| 2017 Q1 | 13.2 Million USD | 16.83% |
| 2017 Q4 | 17.04 Million USD | -22.7% |
| 2017 FY | 71.34 Million USD | -12.46% |
| 2017 Q3 | 22.04 Million USD | 15.67% |
| 2017 Q2 | 19.05 Million USD | 44.37% |
| 2016 Q1 | 29.56 Million USD | 40.12% |
| 2016 FY | 81.5 Million USD | 5.15% |
| 2016 Q4 | 11.29 Million USD | -42.43% |
| 2016 Q3 | 19.62 Million USD | -6.58% |
| 2016 Q2 | 21.01 Million USD | -28.93% |
| 2015 Q1 | 22.59 Million USD | -17.01% |
| 2015 Q3 | 14.46 Million USD | -25.26% |
| 2015 FY | 77.51 Million USD | -4.18% |
| 2015 Q4 | 21.09 Million USD | 45.86% |
| 2015 Q2 | 19.35 Million USD | -14.33% |
| 2014 Q2 | 16.82 Million USD | 47.63% |
| 2014 Q3 | 25.45 Million USD | 51.31% |
| 2014 Q4 | 27.22 Million USD | 6.95% |
| 2014 FY | 80.89 Million USD | 352.02% |
| 2014 Q1 | 11.39 Million USD | 8.72% |
| 2013 Q4 | 10.48 Million USD | 56.57% |
| 2013 Q1 | -1.4 Million USD | 0.0% |
| 2013 FY | 17.89 Million USD | 477.66% |
| 2013 Q3 | 6.69 Million USD | 0.0% |
| 2012 FY | 3.09 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bionano Genomics, Inc. | 9.56 Million USD | -5050.951% |
| Prenetics Global Limited | 8.82 Million USD | -5480.366% |
| Star Equity Holdings, Inc. | 11.92 Million USD | -4031.645% |
| CareDx, Inc | 178.32 Million USD | -176.316% |
| Exact Sciences Corporation | 1.84 Billion USD | 73.301% |
| Exagen Inc. | 29.45 Million USD | -1572.8% |
| Inotiv, Inc. | 165.44 Million USD | -197.831% |
| Guardant Health, Inc. | 336.89 Million USD | -46.259% |
| Biodesix, Inc. | 36.07 Million USD | -1265.801% |
| BioNexus Gene Lab Corp. | 1.32 Million USD | -36962.109% |
| Precipio, Inc. | 6.01 Million USD | -8087.77% |
| iSpecimen Inc. | 5.1 Million USD | -9546.596% |
| Aspira Women's Health Inc. | 5.26 Million USD | -9264.12% |
| Standard BioTools Inc. | 50.45 Million USD | -876.69% |
| 23andMe Holding Co. | 99.37 Million USD | -395.829% |
| Castle Biosciences, Inc. | 174.8 Million USD | -181.878% |
| Personalis, Inc. | 18.2 Million USD | -2606.173% |
| Aclaris Therapeutics, Inc. | 13.16 Million USD | -3641.95% |
| Applied DNA Sciences, Inc. | 5.53 Million USD | -8804.781% |
| OpGen, Inc. | -90.69 Thousand USD | 543399.446% |
| T2 Biosystems, Inc. | -8.17 Million USD | 6131.089% |
| Myriad Genetics, Inc. | 476.4 Million USD | -3.43% |
| ICON Public Limited Company | 1.81 Billion USD | 72.841% |
| NeoGenomics, Inc. | 244.6 Million USD | -101.444% |
| Star Equity Holdings, Inc. | 11.92 Million USD | -4031.645% |
| IDEXX Laboratories, Inc. | 2.18 Billion USD | 77.5% |
| RadNet, Inc. | 93 Million USD | -429.828% |
| MDxHealth SA | 43.92 Million USD | -1021.674% |
| Psychemedics Corporation | 8.41 Million USD | -5756.888% |
| Illumina, Inc. | 2.74 Billion USD | 82.043% |
| Check-Cap Ltd. | -212 Thousand USD | 232524.528% |
| Twist Bioscience Corporation | 133.34 Million USD | -269.512% |
| DarioHealth Corp. | 5.98 Million USD | -8134.291% |
| Fulgent Genetics, Inc. | 104.45 Million USD | -371.72% |
| Sera Prognostics, Inc. | 96 Thousand USD | -513170.833% |
| ENDRA Life Sciences Inc. | -275.45 Thousand USD | 178984.811% |
| OPKO Health, Inc. | 318.12 Million USD | -54.888% |
| Medpace Holdings, Inc. | 524.5 Million USD | 6.056% |
| Neogen Corporation | 463.9 Million USD | -6.217% |
| Intelligent Bio Solutions Inc. | 1.42 Million USD | -34463.062% |
| Prenetics Global Limited | 8.82 Million USD | -5480.366% |
| Mainz Biomed B.V. | 509.65 Thousand USD | -96580.329% |
| bioAffinity Technologies, Inc. | 791.61 Thousand USD | -62144.904% |
| Trinity Biotech plc | 19.45 Million USD | -2433.368% |
| Neuronetics, Inc. | 51.7 Million USD | -852.983% |
| Sotera Health Company | 577.15 Million USD | 14.626% |
| bioAffinity Technologies, Inc. | 791.61 Thousand USD | -62144.904% |